Monday, October 17, 2022 at 11am EDT | 4pm BST | 5pm CEST Why would a CDMO to leverage fixed-bed bioreactor technology to develop and produce GMP lentiviral vectors? Join us for a discussion on increasing quality and decreasing time and cost to accelerate time to clinic and market for lentiviral products with technology.
Lentiviral vectors are efficient ex-vivo and in-vivo gene delivery systems for numerous cell and gene therapies such as chimeric antigen receptor (CAR)-T cell therapy. Like other live agents, lentiviral vectors are highly sensitive to their environment (pH, temperature, shear, chemical composition) and require a careful bioprocess. Structured fixed-bed bioreactors offer a low-shear, well-controlled and homogeneous environment which achieves high productivity, high product quality, and cost-effectiveness in a reduced footprint.
This webinar will provide insights into:
Senior Product &
Alex Chatel is a legacy Univercells team member, joining in 2017 to work on the first NevoLine for Sabin inactivated poliovirus vaccine and the launch of the first scale-X hydro and carbo bioreactor systems. Today, Alex is senior marketing and product manager at Univercells Technologies, a subsidiary company of Univercells, overlooking a portfolio of gene therapy and viral vaccines bioprocessing solutions for Univercells Technologies. He holds a PhD in biochemical engineering from University College London (2014). During his PhD studies, Alex worked with GSK (United Kingdom) on ultra-scale-down bioprocessing tools for domain antibodies, the smallest known antigen binding antibody fragments. Afterwards, Alex served as an Enterprise Fellow at University College London, developing the commercial application of ultra-scale-down bioprocessing, and playing a key role in launching collaborations with several small and large pharmaceutical companies in the European Union and United States. Alex also achieved a master’s degree in chemical engineering from the University of Manchester (2009) and a certificate in New Venture Development from the London Business School (UK).
Natalia Elizalde graduated in pharmacy, developing her end of degree project at UCLH Hospital in London. Afterwards, she was awarded a European PhD as a result of a thesis (University of Navarra; Oxford University) focused on the Long-term effects of Chronic mild stress over behaviour and neurobiological markers (Extraordinary Doctorate award).
After her PhD, Natalia has specialized in business development in the Biotech sector for 10 years, assuming various roles as business development manager in a biotech company specializing in the zebrafish animal model and as head of Business Development at a CDMO developing and manufacturing biologicals and cell therapy products.
Natalia is responsible for VIVEbiotech´s business development strategy with respect to the international market.
Head of the USP
Filipe Cristóvão is a graduate in genetics and biotechnology from the University of Trás-os-Montes and Alto Douro, Portugal, with a Master’s degree in Biotechnology Applied to Health Sciences from the same university. Before joining VIVEbiotech, Filipe worked at the USP Department of a biotechnology CDMO in Spain, both as a scientist and a technician, manufacturing recombinant proteins under GMP standards. Filipe is currently the Head of the USP Development Department at VIVEbiotech.
Time and Date:
Monday, October 17, 2022 at 11am EDT | 4pm BST | 5pm CEST